of0
Export
 
CDE Detailed Report
This report contains detailed information about the selected CDEs.
Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report.
Disease: Chiari I Malformation
Sub-Domain: Functional Outcomes
CRF: Functional Status Karnofsky Score
Item count: 1
CDE ID
CDE Name
Variable Name
Definition / Description
Question Text
Permissible Value
Description
Data Type
Instructions
References
Population
Classification (e.g., Core)
Version #
Version Date
Aliases for Variable Name
CRF Module / Guideline
© or TM
Sub-Domain
Domain
Previous Title
Size
Input Restrictions
Min Value
Max Value
Measurement Type
LOINC ID
SNOMED
caDSR ID
CDISC ID
C21726
Karnofsky modified performance status score
KarnModPerfStScore
Score identifying current level of functioning favoring the highest level estimate.
Modified Karnofsky Score
100;90;80;70;60;50;40;30;20;10;
I feel normal: No complaints. No evidence of disease;I am able to carry on normal activity, with minor symptoms;I carry on normal activity with effort and some symptoms;I am able to care for myself, but unable to carry on normal activities;I require occasional assistance, but can care for most of my needs;I require considerable assistance and frequent care by others;I am disabled. I require considerable assistance and frequent care by others;I am severely disabled. I am hospitalized, but death is not imminent;I am very sick. I require active supportive care by others;I have fatal processes that are rapidly progressing. I am near death;
Alphanumeric
No instructions available
Karnofsky DA, Burchenal JH, Armistead GC, Southam CM, Bernstein JL, Craver LF, Rhoads CP. Triethylene melamine in the treatment of neoplastic disease. Arch Intern Med.1951;87:477–516, 1951.
Adult
Supplemental
1.0
6/1/2016
MKS
Functional Status Karnofsky Score
Functional Outcomes
Outcomes and End Points
  
Single Pre-Defined Value Selected
       
07-22-2019
Page 1 of 1